(Press-News.org) Production of biological substances for medicine using genetically engineered yeast cells shows new promising results in basic research from an international team of researchers. In 2022, the researchers attracted international attention by programming the longest-ever biosynthetic pathway - or 'assembly line' - into a microbial cell factory and designing it to produce biological substances for cancer drugs.
In an article published in the scientific journal Nature Chemical Biology, Biosynthesis of natural and halogenated plant monoterpene indole alkaloids in yeast, the researchers now present results with the artificial production of the naturally occurring substance, alstonine, which has shown promising results for use in treating mental disorders.
"Development of medicines from natural plant substances is widely used. However, since plants do not produce these substances to fight human diseases, there is often a need to modify them to make them more effective and safe," says Michael Krogh Jensen, a senior researcher at DTU Biosustain and co-founder of the biotech company Biomia.
The researchers hope that the yeast platform can play a prominent role in discovering and developing plant-based medicine.
Fewer side effects for patients
The new research results prove that the engineered yeast cells can make other substances in the group of alkaloids than the substance vinblastine, for which the researchers presented results in 2022. In addition to producing the two new natural plant substances, alstonine and serpentine, the researchers have further developed the method to make 19 new derived variants of the two substances through a chemical process called halogenation, often used in medicine development. Today, up to 40 percent of the substances tested in human trials are produced by halogenation.
"We have found a method to make yeast cells use enzymes and carry out the same chemical process that takes place in halogenation. Plants generally can't naturally carry out halogenation. Therefore, our versatile biotechnological platform is a possible method for optimizing and developing plant-based alkaloids that may then be used to make medicines against, for example, schizophrenia, for which there are many negative side effects such as insomnia, weight gain and reduced immunity, when using existing medicines" says Michael Krogh Jensen.
The researchers created the yeast-based cell factories by inserting a large number of genes from plants that can generate biosynthesis of natural plant substances. In addition, they inserted enzymes from bacteria to halogenate these natural substances and tested the production in yeast. Following the conversion into serpentine and alstonine, the substances were purified. The researchers then tested their structure - using an NMR analysis (Nuclear Magnetic Resonance spectroscopy), which looks at the composition of atoms - and investigated their bioactivity in a cell line from monkeys.
Tested in human trials
The researchers have filed a patent application for the manufacture of the chemistry involved and established the company Biomia, which has a license to the patent portfolio that protects the manufacturing method. For drug discovery within part of the chemistry that the researchers presented in their Nature article from 2022 and this new study, Biomia raised 3 million USD in September 2023.
The research into the new yeast-based production of the halogenated plant-inspired natural substances and the 19 variants is still in an early phase, where the researchers are now finding the best candidates to use in treating mental disorders. The candidates must then be prepared for testing in clinical studies. At best, Michael Krogh Jensen expects to be able to send substances derived from alstonine to clinical trials in 2026.
Even if the clinical studies show promising results against schizophrenia or other mental disorders, it will still be at least ten years before the research may lead to new medicines for purchase at pharmacies.
END
Yeast cells can produce drugs for treatment of psychotic disorders
An international team of researchers has demonstrated that genetically engineered yeast cells can produce the natural plant product alstonine, which has shown positive effects in treating schizophrenia.
2023-11-10
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
New work sheds light on inner working of cells
2023-11-10
CÚRAM researchers at University of Galway, together with colleagues at the Centre for Molecular Nanometrology at University of Strathclyde have published work unveiling the inner workings of cells.
Published recently in the German scientific journal Angewandte Chemie, the work provides a deeper understanding of the way components within cells are interconnected. This research has been on the agenda of scientists worldwide for many years, and has yielded plenty of useful information on how certain diseases behave.
Through cellular visualisation using SRS microscopy, ...
Stable and efficient robotic artificial muscles built upon new material combinations
2023-11-10
Actuators, which convert electrical energy into motion or force, play a pivotal role in daily life, albeit often going unnoticed. Soft material-based actuators, in particular, have gained scientific attention in recent years due to their lightweight, quiet operation, and biodegradability. A straightforward approach to creating soft actuators involves employing multi-material structures, such as "pockets" made of flexible plastic films filled with oils and coated with conductive plastics. When subjected to electrical activation, the film displaces the fluid and contracts the pocket, similar to a biological muscle. This system ...
Initial patient dosed in Phase 2a clinical trial evaluating first-in-class human milk-based therapy in patients undergoing stem cell transplantation for blood cancers
2023-11-10
DUARTE, Calif., Nov. 10, 2023 – In a breakthrough for human milk science, researchers at City of Hope, Los Angeles, have dosed the first patient in a Phase 2a clinical trial evaluating a novel therapy for blood cancer patients undergoing allogeneic hematopoietic stem cell transplantation. The investigational treatment, PBCLN-010 in combination with PBCLN-014, combines human milk sugars with a strain of bacteria found in the gut of nursing infants.
“Previous clinical trials of PBCLN-010 + PBCLN-014 have shown that it can safely and predictably control the gut microbiome ...
UVA launches futures initiative to chart next decade in higher ed
2023-11-10
With an eye toward a decade ahead that promises change, opportunity, and challenge, the University of Virginia on Friday launched its Futures Initiative to help plan for the next 10 years in higher education.
Over the next year, a group of thought leaders from across the University, known as the Futures Initiative Group, will examine the current drivers of change in academia, such as artificial intelligence and large language models like ChatGPT, while also looking ahead to the eventual impact of sensor technology, virtual classrooms, the Internet of Things, and myriad other technological changes.
The goal of the initiative—which was announced at Datapalooza 2023, an annual event ...
Regenstrief, IMIA, IAHSI and AMIA hosting mini-summit at AMIA 2023 Annual Symposium to address health effects of climate change
2023-11-10
INDIANAPOLIS -- Regenstrief Institute, the International Medical Informatics Association (IMIA), the International Academy of Health Sciences Informatics (IAHSI) and the American Medical Informatics Association (AMIA) are hosting a mini-summit at the AMIA 2023 Annual Symposium to address how informatics can help resolve health issues caused by climate change. The event will bring together national and international experts to form an informatics infrastructure that will highlight and bring exposure to climate change's effects on health.
The event Mini-Summit 2023 -- Climate and health: How can informatics help? was planned because of the growing awareness around ...
Howard Meyers establishes Meyers Institute for Oncology Nursing with $25 million gift to MD Anderson
2023-11-10
HOUSTON ― Howard Meyers, of Dallas, Texas, a member of The University of Texas MD Anderson Cancer Center Board of Visitors (BOV), has committed $25 million to The University of Texas MD Anderson Cancer Center to establish the Meyers Institute for Oncology Nursing. The first of its kind, the Meyers Institute for Oncology Nursing will support and develop nurses throughout their careers by providing educational, professional and wellness-based resources tailored to cancer care nurses and nurse scientists. This ...
Clinical trial in pregnant women addresses detection of heart disorder in the fetus
2023-11-10
Some individuals with anti-Ro/SSA antibodies (anti–Sjögren's-syndrome–related antigen A autoantibodies, also called anti-Ro antibodies) have autoimmune diseases such as lupus or Sjögren's syndrome, but many have no symptoms. A clinical trial published in Arthritis & Rheumatology found that high levels of these antibodies in pregnant women are associated with fetal atrioventricular block (AVB), which occurs when inflammation and subsequent scarring prevent electric signals from the heart’s atria from reaching the ventricles. The disease ...
Trial generates promising results for obinutuzumab in patients with lupus nephritis
2023-11-10
In a post hoc analysis of the phase 2 NOBILITY trial, researchers found that treatment with obinutuzumab—an antibody that targets a protein expressed on certain immune cells—was superior to placebo for preserving kidney function and preventing flares in patients with lupus nephritis, a kidney condition associated with the autoimmune disease lupus.
In the analysis, which is published in Arthritis & Rheumatology, compared with standard-of-care treatment alone, the addition of obinutuzumab to lupus nephritis treatment reduced the risk of developing a composite outcome of death, fall in kidney function, or treatment failure by 60%. Adding obinutuzumab ...
Leading cardiologists reveal new heart disease risk calculator
2023-11-10
Statement Highlights:
The new American Heart Association PREVENTTM risk calculator estimates the 10- and 30-year risk of total cardiovascular disease for people aged 30 years and older.
The calculator estimates the risk of heart attack, stroke and — for the first time — heart failure. The equations are sex-specific and race-free, acknowledging that race is not a biological factor, and can include an index of social determinants of health.
This is the first risk calculator that combines measures of cardiovascular, kidney ...
Physical fitness since childhood predicts cerebellar volume in adolescence
2023-11-10
Physical fitness since childhood is associated with cerebellar grey matter volume in adolescents. According to a recent study conducted at the University of Jyväskylä and the University of Eastern Finland, those who were stronger, faster and more agile, in other words, had better neuromuscular fitness since childhood, had larger Crus I grey matter volume in adolescence.
Despite the importance of the developing cerebellum on cognition and learning, the associations between physical fitness and cerebellar volume in adolescents have remained unclear. This study examined the associations ...
LAST 30 PRESS RELEASES:
New review highlights significant need for comprehensive care for gun violence survivors
Crop monitoring system utilizing IoT, AI and other tech showcased at ASABE
Simple algorithm paired with standard imaging tool could predict failure in lithium metal batteries
Can botox be used to alleviate pain in a jaw disorder?
Why “sleeping on it” may improve learning and memory
From faces to feelings: How children learn to read emotions
Pan Feng’s team advances inverse design of catalytic materials with topological AI
Lab to industry: InSe wafer-scale breakthrough for future electronics
August Issues of APA journals feature new research on psychiatric genetics, telehealth prescribing of controlled substances, mental health advocacy, and more
Pioneering AI approach enhances prediction of complex astrochemical reactions
Gigantic, meat-eating dinosaurs didn’t all have strong bites
Researchers discover cause of sea star wasting disease
Less processed diet may be more beneficial for weight loss
New research on colorectal cancer incidence, screening among younger US adults
New therapy outperforms standard treatment in reducing binge eating among veterans
Influenza with and without oseltamivir treatment and neuropsychiatric events among children and adolescents
Oral semaglutide in an East Asian population with overweight or obesity, with or without type 2 diabetes
Glucagon-like peptide-1 receptor agonist eligibility among US adolescents and young adults
Residential care increases social participation but gaps remain
Scientists achieve megabase-scale precision genome editing in eukaryotic cells
National Science Foundation renews Brown’s national mathematics institute with $16.5 million
New tool helps seniors reduce unnecessary medications
Lehigh University Professor Christopher J. Kiely receives top microanalysis award for TEM research
Tomatoes in 3D: Breakthrough in plant monitoring
A novel highly porous dual-phase high-entropy ultrahigh-temperature ceramic with outstanding properties
Study finds gaps in books on consent education for children
New method to steer electricity in atom-thin metals may revolutionize devices
New study: Powerboats can impact lakes below the surface
Plan, prepare, conquer: predicting mountain accident risks with deep learning and pre-climb data
New ancient marine reptile species discovered in Germany's famous Jurassic fossil beds
[Press-News.org] Yeast cells can produce drugs for treatment of psychotic disordersAn international team of researchers has demonstrated that genetically engineered yeast cells can produce the natural plant product alstonine, which has shown positive effects in treating schizophrenia.